CancerDrs

Leukemia clinical trials in Louisiana

18 actively recruiting leukemia trials at 7 sites across Louisiana.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Louisiana:
  • Children's Hospital New Orleans — New Orleans, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Louisiana:
  • Children's Hospital New Orleans — New Orleans, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…

Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Louisiana:
  • Our Lady of the Lake Hospital — Baton Rouge, Louisiana
  • Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
  • Ochsner Clinic Foundation — New Orleans, Louisiana
Phase 3 Recruiting Industry

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …

Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Louisiana:
  • Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
Phase 3 Recruiting Industry

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding r…

Sponsor: Syndax Pharmaceuticals
NCT ID: NCT07211958
Sites in Louisiana:
  • Clinical Trial Site — Shreveport, Louisiana
Phase 2 Recruiting NIH

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Louisiana:
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting NIH

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Louisiana:
  • LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
  • Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
  • Our Lady of The Lake — Baton Rouge, Louisiana
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Louisiana:
  • Children's Hospital New Orleans — New Orleans, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Louisiana:
  • Children's Hospital New Orleans — New Orleans, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Louisiana:
  • Children's Hospital New Orleans — New Orleans, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Louisiana:
  • Children's Hospital New Orleans — New Orleans, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting NIH

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06917911
Sites in Louisiana:
  • Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
Phase 1 Recruiting Industry

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Louisiana:
  • Ochsner MD Anderson Cancer Center — Jefferson, Louisiana
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Louisiana:
  • LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
  • Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
  • Our Lady of The Lake — Baton Rouge, Louisiana
  • Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
  • Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
Recruiting Network

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated i…

Sponsor: Children's Oncology Group
NCT ID: NCT00736749
Sites in Louisiana:
  • Tulane University Health Sciences Center — New Orleans, Louisiana
  • Children's Hospital New Orleans — New Orleans, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Recruiting Network

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…

Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in Louisiana:
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana:
  • Massive Bio SYNERGY-AI site — New Orleans, Louisiana
NA Recruiting Academic/Other

Multicenter HomeVENT: Home Values and Experiences Navigation Track

This is a multicenter study to test a decision-making support process for families and clinicians facing decisions about chronic home ventilation for a child. The investigators hypothesize that the intervention will increase family prepare…

Sponsor: Johns Hopkins University
NCT ID: NCT06102330
Sites in Louisiana:
  • Children's Hospital New Orleans — New Orleans, Louisiana

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09